Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)

Exclusion Criteria

• •1. Women during pregnancy or lactation, and fertile women that are not willing to take contraceptive measurements;
• •2. Patients with other malignant tumors simultaneously that have not been effectively controlled;
• •3. Patients with history of using HDAC inhibitors;
• •4. Patients who are allergic to medicine used in the trial, or have metabolic disorders toward these medicine;
• •5. Patients with severe active infection;
• •6. Patients with HIV or syphilis infection;
• •7. Patients with prolonged QT interval (male \> 450ms，female \> 470ms), or chronic heart failure patients with level III or IV cardiac function; or those have the following heart disease within 6 months before enrollment: acute coronary syndrome, acute heart failure (heart function level III or IV), distinctive ventricular arrhythmias (prolonged ventricular tachycardia, ventricular fibrillation, etc);
• •8. Patients with history of organ transplantation;
• •9. Patients with history of thrombosis and embolism;
• •10. Patients with mental disorders or those who are unable to sign a written consent;
• •11. Patients with drug abuse or long-time alcoholism that may influence the result of the trial;
• •12. Patients who do not have capacity of legal transactions;
• •13. Patients currently in other clinical trials;
• •14. Those who are recognized as inappropriate for the trial by the investigators;